James Molloy

Chad Yahn

- Theriva Biologics (TOVX) announced upcoming presentations at medical meetings for its drug candidates, **VCN-01** and **SYN-004**, on **October 20, 2025**.  **[894158_0001104659-25-098882_tm2528558d1_ex99-1.htm:0]** **[894158_0001104659-25-098882_tm2528558d1_8k.htm:1]** 
- Expanded data from the **VIRAGE Phase 2b trial** for **VCN-01** in metastatic pancreatic cancer (mPDAC) will be presented at ESMO 2025.  **[894158_0001104659-25-098882_tm2528558d1_ex99-1.htm:0]** **[894158_0001104659-25-098882_tm2528558d1_8k.htm:1]** **[894158_0001104659-25-098882_tm2528558d1_8k.htm:2]** 
- The VIRAGE Phase 2b trial met its primary endpoints, demonstrating improved **Overall Survival (OS)**, **Progression-Free Survival (PFS)**, and **Duration of Response (DoR)** for patients receiving VCN-01 plus standard of care chemotherapy.  **[894158_0001104659-25-098882_tm2528558d1_8k.htm:1]** **[894158_0001104659-25-098882_tm2528558d1_8k.htm:2]** **[894158_0001104659-25-098882_tm2528558d1_ex99-2.htm:2]** 
- In the full analysis set (FAS) population, OS was **10.8 months** for the VCN-01 + GA arm versus **8.6 months** for the GA-only arm, and PFS was **7.0 months** versus **4.6 months**, respectively.  **[894158_0001104659-25-098882_tm2528558d1_8k.htm:1]** **[894158_0001104659-25-098882_tm2528558d1_8k.htm:2]** **[894158_0001104659-25-098882_tm2528558d1_ex99-2.htm:2]**